Sanofi Contingent Value Rights
GCVRZ
GCVRZ was delisted on the 3rd of March, 2020.
1 hedge funds and large institutions have $1 invested in Sanofi Contingent Value Rights in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
50% less funds holding
Funds holding: 2 → 1 (-1)
100% less capital invested
Capital invested by funds: $3M → $1 (-$3M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DMKJ
David M. Knott Jr
|
-$3M |
GCVRZ Hedge Fund Activity: Q4 2023 in Review
1 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q4 2023, worth a combined $1 — down 100% from $3M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of GCVRZ and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was David M. Knott Jr, exiting entirely with an estimated $3M sold.
- 1 institutional investor held Sanofi Contingent Value Rights (GCVRZ) as of Q4 2023, down from 2 in Q3 2023.
- Funds reported $1 of Sanofi Contingent Value Rights stock for Q4 2023, down 100% quarter-over-quarter.
- 0 funds opened new Sanofi Contingent Value Rights positions in Q4 2023 and 1 closed out, a net change of -1 holder.
- The largest Sanofi Contingent Value Rights seller in Q4 2023 was David M. Knott Jr, an estimated $3M sold.
Based on aggregated 13F filings for Q4 2023.